Studies have shown that therapies that break the PD-1 and PD-L1 interaction such as pembrolizumab, nivolumab, atezolizumab, and avelumab had an anti-tumour effect on melanoma, non-small cell lung carcinoma, renal cell cancer, and Hodgkin lymphoma. This evidence concerns the gene CD274 and renal cell adenocarcinoma.